Volume 15, Number 10—October 2009
Research
Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy
Table 3
Characteristics of 105 pulmonary and nonpulmonary anti–TNF-α therapy–associated cases of NTM disease, US Food and Drug Administration MedWatch database, 1999–2006*
Characteristic | Pulmonary (n = 59), no. (%) | Extrapulmonary (n = 46), no. (%) |
---|---|---|
Mycobacterium avium | 43 (73) | 9 (20)† |
RGM | 6 (10) | 15 (33)† |
Age, y | 61 | 63 |
Female patient | 41 (73) | 25 (54)† |
Rheumatoid arthritis | 48 (81) | 25 (54)† |
Infliximab | 40 (68) | 33 (72) |
Etanercept | 13 (22) | 12 (26) |
*TNF-α, tumor necrosis factor-α; NTM, nontuberculous mycobacteria; RGM, rapidly growing mycobacteria.
†p<0.05 for comparison of pulmonary disease and extrapulmonary disease.